Register entry
ENTASIS THERAPEUTICS INC
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 10
- Exclusivities
- 2
- Countries
- 0
Exclusivity
Patents and exclusivities
10| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 9040528 | NUZOLVENCEzoliflodacin | use | Oct 2029 |
| 8658641 | NUZOLVENCEzoliflodacin | substance | Jun 2030 |
| 9309245 | XACDURO (COPACKAGED)durlobactam sodium; durlobactam sodium; sulbactam sodium | substance | Apr 2033 |
| 9623014 | XACDURO (COPACKAGED)durlobactam sodium; durlobactam sodium; sulbactam sodium | use | Apr 2033 |
| 8889671 | NUZOLVENCEzoliflodacin | substance | Jan 2034 |
| 9187495 | NUZOLVENCEzoliflodacin | substance | Jan 2034 |
| 9540394 | NUZOLVENCEzoliflodacin | use | Jan 2034 |
| 9839641 | NUZOLVENCEzoliflodacin | use | Jan 2034 |
| 10376499 | XACDURO (COPACKAGED)durlobactam sodium; durlobactam sodium; sulbactam sodium | product | Nov 2035 |
| 9968593 | XACDURO (COPACKAGED)durlobactam sodium; durlobactam sodium; sulbactam sodium | product | Nov 2035 |
| Product | Exclusivity | Until |
|---|---|---|
| NUZOLVENCEZOLIFLODACIN | GAIN Qualified infectious disease product (GAIN) | Dec 2035 |
| XACDURO (COPACKAGED)DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM | GAIN Qualified infectious disease product (GAIN) | May 2033 |
Enquiry
Common questions
- Is ENTASIS THERAPEUTICS INC FDA approved?
- ENTASIS THERAPEUTICS INC holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.